Top Page
Nanosonics Limited
(Sydney:NAN)
Nanosonics Limited (NAN) vs. iShares MSCI Australia ETF (EWA)
Nanosonics Limited Business Overview & Revenue Model
Nanosonics Limited Earnings Call Summary
Nanosonics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 198.52M | 198.93M | 171.56M | 167.51M | 119.73M | 101.83M |
| Gross Profit | 155.25M | 155.66M | 133.99M | 125.66M | 86.15M | 74.91M |
| EBITDA | 26.04M | 31.82M | 21.72M | 29.50M | 7.86M | 15.75M |
| Net Income | 20.68M | 20.68M | 12.97M | 19.88M | 3.74M | 8.58M |
Balance Sheet | ||||||
| Total Assets | 272.48M | 272.48M | 237.34M | 226.07M | 193.24M | 164.57M |
| Cash, Cash Equivalents and Short-Term Investments | 161.29M | 161.29M | 129.55M | 112.16M | 94.51M | 96.03M |
| Total Debt | 7.69M | 7.69M | 9.30M | 10.72M | 11.71M | 2.49M |
| Total Liabilities | 62.57M | 62.57M | 55.14M | 62.22M | 54.55M | 29.01M |
| Stockholders Equity | 209.91M | 209.91M | 182.20M | 163.86M | 138.69M | 135.57M |
Cash Flow | ||||||
| Free Cash Flow | 35.26M | 35.26M | 20.27M | 19.74M | -271.00K | 5.93M |
| Operating Cash Flow | 43.98M | 43.98M | 22.78M | 23.31M | 6.70M | 7.32M |
| Investing Cash Flow | -8.71M | -8.71M | -2.36M | -3.54M | -6.90M | -1.38M |
| Financing Cash Flow | -3.30M | -3.30M | -3.01M | -2.71M | -1.97M | -1.03M |
Nanosonics Limited Technical Analysis
Nanosonics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$111.73M | 9.19 | 12.37% | 3.62% | -0.74% | 16.65% | |
68 Neutral | $1.21B | 58.30 | 10.32% | ― | 15.60% | 58.74% | |
67 Neutral | AU$164.89M | 26.99 | 12.35% | ― | 39.98% | -30.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$274.30M | -78.71 | -4.06% | ― | 20.36% | 64.81% | |
47 Neutral | AU$119.74M | -26.79 | -4.28% | ― | 7.38% | 82.39% | |
46 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Nanosonics Limited Corporate Events
Nanosonics Limited has appointed William Haydon as the Regional President for North America, effective December 1, 2025, following the retirement of Ken Shaw. Haydon’s extensive experience in the medical device and healthcare technology sectors, particularly in infection prevention and endoscope reprocessing, aligns with Nanosonics’ strategic priorities as it prepares to commercialize its CORIS® platform, marking a significant step in its growth strategy.
The most recent analyst rating on (AU:NAN) stock is a Sell with a A$4.10 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Nanosonics Limited as of November 3, 2025. This change in shareholding could impact the company’s shareholder structure and influence its market perception, potentially affecting investor confidence and the company’s strategic decisions.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited held its 2025 Annual General Meeting where all proposed resolutions were successfully carried. The meeting also marked the departure of Dr. Lisa McIntyre from the Board, as previously announced. This outcome reflects strong shareholder support and continuity in the company’s strategic direction, potentially reinforcing its market position and stakeholder confidence.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, reflecting its strong financial position and confidence in long-term growth. This initiative is part of the company’s capital management strategy, supported by its cash reserves and history of predictable cash flows, and aims to deliver long-term value to shareholders while maintaining a strong balance sheet and investing in future growth opportunities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for quotation of 189,870 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move, involving securities issued under an employee incentive scheme, is part of the company’s strategic efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for the quotation of 53,069 ordinary fully paid securities on the ASX. These securities are issued under an employee incentive scheme, reflecting the company’s ongoing efforts to incentivize and retain talent, which may enhance its operational capabilities and market position.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced its 2025 Annual General Meeting (AGM), which will be held as a hybrid event, allowing shareholders to participate either in person or online. This approach aims to increase accessibility and engagement, enabling shareholders to ask questions and vote in real time, reflecting the company’s commitment to transparency and stakeholder involvement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.90 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in the director’s interest, specifically regarding Mr. Michael Kavanagh’s holdings. The change involved the exercise of performance and service rights under the Nanosonics Omnibus Equity Plan, resulting in the acquisition of 109,685 ordinary shares. This adjustment in the director’s holdings reflects the company’s ongoing commitment to aligning management interests with shareholder value, potentially impacting investor confidence and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the issuance of 289,148 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding and retaining its workforce, potentially strengthening its market position and operational capabilities.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in the director’s interest, with Gerard Dalbosco acquiring an additional 12,558 ordinary shares, increasing his total to 40,000 shares. This transaction, valued at approximately $51,231.58, reflects a strategic move in the company’s governance, potentially impacting shareholder confidence and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced that Dr. Lisa McIntyre will not seek re-election and will step down from the Board on November 5, 2025. Dr. McIntyre has been a significant contributor to the company, particularly as Chair of the Innovation & Development Committee. Her departure prompts the company to begin a search for a new director. Dr. Larry Marshall will take over as Chair of the Innovation & Development Committee. This leadership change reflects Nanosonics’ ongoing commitment to innovation and maintaining strong governance.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited’s recent earnings call reflected a slightly positive sentiment, underscored by robust financial and operational results. The company reported significant revenue growth and successful product launches, despite facing challenges such as tariff impacts and slow progress in the Japanese market. The strategic advancements and sustainability initiatives further contributed to the positive outlook.
Nanosonics Limited, an Australian company, specializes in infection prevention technologies, particularly in the healthcare sector, with its flagship product being the trophon technology for ultrasound probe disinfection. In its 2025 annual report, Nanosonics highlighted a strong financial performance with a 17% increase in revenue, reaching $198.6 million, and a 72% rise in profit before tax to $22.3 million. The company’s growth was driven by a significant increase in recurring revenue and strategic investments in R&D and operational advancements. Key developments included the launch of the next-generation trophon3 and the FDA clearance for CORIS, a device for endoscope cleaning, which is expected to open new market opportunities. Looking ahead, Nanosonics is optimistic about continued growth, focusing on expanding its product portfolio and market presence while navigating global trade challenges.
Nanosonics Limited reported strong financial results for the full year 2025, showcasing a 17% year-over-year increase in total revenue to $198.6 million. The company’s recurring revenue, which includes consumables and services, grew by 20% to $146.1 million, highlighting the robustness of its business model. Capital revenue also saw a 9% increase, while the gross profit margin slightly improved to 78.2%. Operating expenses rose by 10%, but the consolidated profit before tax surged by 72% to $22.3 million, indicating a solid financial performance and positive outlook for stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited reported a strong financial performance for FY25, with a 17% increase in total revenue to $198.6 million and a 72% rise in profit before tax. The company achieved significant milestones, including the launch of next-generation trophon technology and FDA clearance for its CORIS system, which is expected to enhance its market leadership and expand its portfolio. The company’s strategic investments in R&D and operational advancements, such as a new US manufacturing facility, are set to support future growth and shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has released its Annual Report for 2025, detailing its financial and operational performance over the past year. The report highlights the company’s commitment to sustainability and includes updates on its key products, trophon®2 and CORIS®. The release of this report is a significant event for stakeholders as it provides insights into the company’s strategic direction and operational priorities, which may influence its market positioning and future growth prospects.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited’s Sustainability Report for FY25 highlights the company’s significant impact on infection prevention, having protected over 28 million patients from cross-contamination risks. The report outlines Nanosonics’ commitment to sustainability, detailing its performance and future targets, which are crucial for its operations and stakeholder engagement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is accessible on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s recommendations, including board responsibilities, director appointments, and accountability measures, reflecting its commitment to transparency and robust governance practices.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has released its Corporate Governance Statement, affirming its commitment to good corporate governance in line with the Australian Securities Exchange (ASX) guidelines. The statement outlines the company’s adherence to ASX Corporate Governance Principles and Recommendations, emphasizing the clear distinction of roles between the Board and senior executives, and the Board’s ultimate authority over management. This governance framework aims to enhance the company’s strategic implementation and performance oversight, benefiting all stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.15 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.